Showing results (61-70 of 153) with videos related to

Sort By:
Pageof 16
Hepato-Gastroenterology|March 11, 2010
Clinical evaluation of endosonography-guided biliary drainage for patients with the difficulty with placing of internal drainageYuji Sakai, Takeshi Ishihara, Toshio Tsuyuguchi, et al.
BMC Gastroenterology|July 13, 2016
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case reportYuki Ohta, Tatsuo Kanda, Tatsuro Katsuno, et al.
Clinical Journal of Gastroenterology|May 13, 2016
Autoimmune hepatitis following drug-induced liver injury in an elderly patientJunichiro Kumagai, Tatsuo Kanda, Shin Yasui, et al.
International Journal of Medical Sciences|June 10, 2016
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in JapanTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Plos One|July 8, 2014
Suppression of La antigen exerts potential antiviral effects against hepatitis A virusXia Jiang, Tatsuo Kanda, Shuang Wu, et al.
Case Reports in Gastroenterology|January 20, 2017
Drug-Induced Liver Injury Associated with Complementary and Alternative MedicinesKoji Takahashi, Tatsuo Kanda, Shin Yasui, et al.
International Journal of Medical Sciences|January 8, 2014
Ultra-deep sequencing analysis of the hepatitis A virus 5'-untranslated region among cases of the same outbreak from a single sourceShuang Wu, Shingo Nakamoto, Tatsuo Kanda, et al.
Plos One|September 27, 2013
Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific regionShuang Wu, Tatsuo Kanda, Shingo Nakamoto, et al.
Case Reports in Gastroenterology|August 14, 2015
Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor GenotypeTatsuo Kanda, Masato Nakamura, Reina Sasaki, et al.
International Journal of Medical Sciences|April 15, 2016
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus RibavirinTatsuo Kanda, Shingo Nakamoto, Reina Sasaki, et al.
Pageof 16